Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Nov;56(9):1361-1369.
doi: 10.1111/apt.17224. Epub 2022 Sep 27.

Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study

Irit Avni-Biron  1   2 , Tali Mishael  3   4 , Eran Zittan  5 , Moran Livne-Margolin  2   6 , Adar Zinger  4   7 , Roie Tzadok  2   8 , Rosie Goldenberg  3 , Uri Kopylov  2   6 , Yulia Ron  2   8 , Eran Hadar  2   9 , Sarit Helman  3   4 , Sorina Grisaru Granovsky  3   4 , Jacob E Ollech  1   2 , Ayelet Arazi  5 , Rivka Farkash  3   4 , Maor H Pauker  1 , Henit Yanai  1   2 , Iris Dotan  1   2 , Ariella Bar-Gil Shitrit  3   4
Affiliations
Multicenter Study

Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study

Irit Avni-Biron et al. Aliment Pharmacol Ther. 2022 Nov.

Abstract

Background: Women with inflammatory bowel diseases (IBD) often receive biologics to maintain remission during pregnancy.

Aims: To assess maternal and neonatal outcomes in patients with IBD treated with ustekinumab (UST) during pregnancy METHODS: In a multicentre, prospective cohort study, we recruited women with IBD treated with UST during pregnancy between 2019 and 2021. Outcomes were compared among patients treated with UST, anti-tumour necrosis factor α, (anti-TNF) and non-UST, non-anti-TNF therapies. UST-treated patients were matched 1:2 to controls according to age, body mass index and parity. Newborns were followed up to 12 months.

Results: We recruited 129 pregnant patients: UST 27; anti-TNF 52; non-UST, non-anti-TNF 50 (thiopurine or mesalazine 30, no therapy 20); Crohn's disease 25 (96.9%). Overall, pregnancy, neonatal and newborn outcomes were satisfactory, with no significant differences among patients treated with UST, anti-TNF and non-UST non-anti-TNF agents for obstetrical maternal complications [UST 3 (11.5%), anti TNF 12 (23.1%), non UST, non-anti-TNF 4 (8.2%), p = 0.095], pre-term delivery [1 (4.3%), 9 (18.4%), 4 (5.7%), p = 0.133], low birth weight [1 (4.2%), 5 (10.2%), 4 (8.3%), p = 0.679], or first year newborn hospitalisation [2 (9.1%), 4 (8.2%), 3 (6.1%), p = 0.885].

Conclusion: Pregnant patients with IBD treated with UST demonstrated favourable pregnancy and neonatal outcomes that were comparable with those in patients treated with anti-TNF or other therapy. Data are reassuring for patients with IBD and their physicians when considering UST during pregnancy.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western countries. Gastroenterology. 2018;155:1079-1089.e3. https://doi.org/10.1053/j.gastro.2018.06.043
    1. Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. Gastroenterology. 2019;156:1508-24. https://doi.org/10.1053/j.gastro.2018.12.022
    1. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734-757.e1. https://doi.org/10.1053/j.gastro.2015.12.003
    1. van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn's Colitis. 2015;9:107-24. https://doi.org/10.1093/ecco-jcc/jju006
    1. Bar-Gil Shitrit A, Ben Ya'Acov A, Livovsky DM, Cuker T, Farkash R, Hoyda A, et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol. 2019;114:1172-5. https://doi.org/10.14309/ajg.0000000000000186

Publication types

LinkOut - more resources